Iodixanol
As of the edition of 20 October 2026, Iodixanol is a drug: marketed, first approved in 1995 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Unknown
- Brand name
- Visipaque 270
- First approved
- 1 June 1995 (ES)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- GE HEALTHCARE DO BRASIL COMÉRCIO E SERVIÇOS PARA EQUIPAMENTOS M; 4 holders in all
- Registered trials
- 24, 9 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Cancer; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 3 | 0 | 3 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 3 | 3 | 1 | 0 | 2 |
| Phase 4 | 13 | 9 | 0 | 3 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Applicant and Lead sponsor of trials | 1996 to now |